Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)

Area of Science:

• Neuroimmunology
• Oncology
• Immunotherapy

Background:

• Aging patients with multiple sclerosis (MS) face increased cancer risk.
• Immune checkpoint inhibitors (ICIs) are effective cancer treatments but carry risks of immune-related adverse events.
• Concerns exist regarding ICI use in MS patients due to potential exacerbation of autoimmune disease.

Purpose of the Study:

• To review the safety and efficacy of ICIs in patients with MS.
• To explore novel therapeutic strategies for MS, including CAR-T cell and anti-CD40L treatments.
• To assess the potential of new therapies to target central nervous system inflammation in progressive MS.

Main Methods:

• Review of current clinical data on ICI use in MS patients.
• Discussion of immune-related adverse events associated with ICIs.
• Exploration of emerging MS therapies and their mechanisms of action.

Main Results:

• Current data suggest ICIs are generally well-tolerated in MS patients regarding MS disease activity.
• MS should not be an absolute contraindication for ICI use; individualized risk-benefit assessment is recommended.
• Novel therapies like CAR-T cells and anti-CD40L can cross the blood-brain barrier.

Conclusions:

• ICI use in MS patients appears safe from an MS disease activity perspective, warranting personalized risk-benefit evaluations.
• Emerging therapies hold significant potential for treating progressive MS by targeting localized neuroinflammation.
• New treatments may address unmet needs in managing the pathophysiology of progressive MS.